Report by : Gan Yung Chyan
/ KUCINTA SETIA
Pictures posted on the Internet show that as early as 26 February 2020, the Academy of Military Medical Sciences of the Academy of Military Sciences and Cosino Biotechnology Co., Ltd. have produced a "recombinant novel coronavirus vaccine". Image : Web screenshot.
The China Communist Party(CCP) announced that the virus SARS-CoV-2 (covi, in short) vaccine developed by Chen Wei, a biochemical weapon expert, has begun clinical trials. Wang Hao, a Taiwanese financial writer, pointed out that according to official calculations, Chen Wei may have started research and development of covi vaccine in September 2019.
According to the CCTV report, on 16 March 2020, the "recombinant novel coronavirus vaccine" developed by the academician Chen Wei's team of the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences was approved to start clinical trials. The Chen Wei team arrived in Wuhan on 26 January 2020 and began developing vaccine in advance for safe, effective, controllable quality, and large-scale production in accordance with "international norms" and "domestic regulations."
However, the World Health Organization (WHO) used the influenza virus as an example to show that it takes about 5 to 6 months to produce a covi vaccine after identifying and isolating a new virus strain. These months are necessary because the production of a new vaccine involves many steps. Each step takes some time to complete.
Wang Hao, a Taiwan-based financial writer born in Shanghai, also quoted China media on Facebook, saying that the production cycle of this vaccine takes 5 to 6 months. Based on this calculation, Chen started to research and develop covi vaccine around September 2019. Then whose "genome sequence" did she base on to develop the vaccine?
Image : An extract of the Hubei Daily news on the "Novel Coronavirus Emergency Response" exercise in Wuhan on 18 September 2019, reproduced on the official web-site of Xinhua News Agency.
Wang Hao also mentioned that on 18 September 2019, one month before the opening of the World Military Games in Wuhan, the Chinese government held a "Novel Coronavirus Emergency Response" exercise in Wuhan. According to Xinhua News Agency and Hubei Daily, this exercise took place at Wuhan Tianhe International Airport. This seems to coincide with a possible point in time for the above-mentioned vaccine development.
If Wang Hao's doubt is credible, more questions will arise. Could the disease COVID-19 (covid, in short) or novel coronavirus have emerged as far back as autumn in China or earlier or has the virus naturally evolved since China last declared the "disappearance of SARS"? When was the term "novel coronavirus" (新型冠状病毒) first used in mainland China since the name appeared in the Wuhan emergency response exercise in September 2019 and not in December 2019? CCP should take the responsibility to address these questions in a scientific way.
According to the vaccine picture disclosed by the CCP's military network, as early as 26 February 2020, the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences and CanSino Biologics Inc. have cooperated to produce a "recombinant novel coronavirus vaccine." Similar pictures have flowed out on the Internet earlier.
On 18 March 2020, CanSino Biologics Inc., a Hong Kong Stock Exchange-listed company headquartered in Tianjin, announced that the new recombinant coronavirus vaccine (adenovirus vector) (Ad5-nCoV) jointly developed by the company and the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences has passed the clinical research registration review and approved for clinical trials. Ad5-nCoV is constructed by genetic engineering method. It uses replication-defective human type 5 adenovirus as a vector to express the novel coronavirus S antigen and is intended to prevent diseases caused by covi infection.
However, CanSino Biologics Inc. informed the media that it cannot assure that the vaccine can be successfully developed and registered for clinical sale and worldwide vaccination to eliminate covi since clinical trials are underway in Wuhan.
Image courtesy : Gong Renchao, student of Wuhan University vaccinated with Ad5-nCoV in Wuhan on 20 March 2020.
CanSino Biologics Inc. is known for successfully developing and selling the first Ebola vaccine in partnership with the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences.
Since the outbreak, covi has been widely questioned related to the Wuhan Institute of Virology and now the vaccine development has been questioned on the background of the "Novel Coronavirus Emergency Response" exercise in Wuhan.
Although overseas experts have also pointed out the characteristics of the virus's suspected artificial synthesis, there is no direct evidence at present.
Researcher Shi Zhengli of the Wuhan P4 Laboratory of the Wuhan Insititute of Virology is a coronavirus expert. In 2015, she participated in the development of a new coronavirus that can bind to human angiotensin-converting enzyme 2 (ACE2). This coronavirus transmission mode to humans is similar to covid. Last year, the virus research institute also successfully discovered a new type of coronavirus that killed a large number of pigs. After the outbreak in Wuhan in January this year, Chen Wei, a CCP military biochemical weapon expert from the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences, went south to Wuhan, and it was reported that she secretly took over the P4 laboratory of the Wuhan virus research institute.
Web Refs:
https://www.ntdtv.com/gb/2020/03/23/a102806599.html
http://www.nbd.com.cn/articles/2020-03-18/1417767.html
http://m.xinhuanet.com/hb/2019-09/26/c_1125040756.htm
https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=400167
https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=407064
/ KUCINTA SETIA
Pictures posted on the Internet show that as early as 26 February 2020, the Academy of Military Medical Sciences of the Academy of Military Sciences and Cosino Biotechnology Co., Ltd. have produced a "recombinant novel coronavirus vaccine". Image : Web screenshot.
The China Communist Party(CCP) announced that the virus SARS-CoV-2 (covi, in short) vaccine developed by Chen Wei, a biochemical weapon expert, has begun clinical trials. Wang Hao, a Taiwanese financial writer, pointed out that according to official calculations, Chen Wei may have started research and development of covi vaccine in September 2019.
According to the CCTV report, on 16 March 2020, the "recombinant novel coronavirus vaccine" developed by the academician Chen Wei's team of the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences was approved to start clinical trials. The Chen Wei team arrived in Wuhan on 26 January 2020 and began developing vaccine in advance for safe, effective, controllable quality, and large-scale production in accordance with "international norms" and "domestic regulations."
However, the World Health Organization (WHO) used the influenza virus as an example to show that it takes about 5 to 6 months to produce a covi vaccine after identifying and isolating a new virus strain. These months are necessary because the production of a new vaccine involves many steps. Each step takes some time to complete.
Wang Hao, a Taiwan-based financial writer born in Shanghai, also quoted China media on Facebook, saying that the production cycle of this vaccine takes 5 to 6 months. Based on this calculation, Chen started to research and develop covi vaccine around September 2019. Then whose "genome sequence" did she base on to develop the vaccine?
Image : An extract of the Hubei Daily news on the "Novel Coronavirus Emergency Response" exercise in Wuhan on 18 September 2019, reproduced on the official web-site of Xinhua News Agency.
Wang Hao also mentioned that on 18 September 2019, one month before the opening of the World Military Games in Wuhan, the Chinese government held a "Novel Coronavirus Emergency Response" exercise in Wuhan. According to Xinhua News Agency and Hubei Daily, this exercise took place at Wuhan Tianhe International Airport. This seems to coincide with a possible point in time for the above-mentioned vaccine development.
If Wang Hao's doubt is credible, more questions will arise. Could the disease COVID-19 (covid, in short) or novel coronavirus have emerged as far back as autumn in China or earlier or has the virus naturally evolved since China last declared the "disappearance of SARS"? When was the term "novel coronavirus" (新型冠状病毒) first used in mainland China since the name appeared in the Wuhan emergency response exercise in September 2019 and not in December 2019? CCP should take the responsibility to address these questions in a scientific way.
According to the vaccine picture disclosed by the CCP's military network, as early as 26 February 2020, the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences and CanSino Biologics Inc. have cooperated to produce a "recombinant novel coronavirus vaccine." Similar pictures have flowed out on the Internet earlier.
On 18 March 2020, CanSino Biologics Inc., a Hong Kong Stock Exchange-listed company headquartered in Tianjin, announced that the new recombinant coronavirus vaccine (adenovirus vector) (Ad5-nCoV) jointly developed by the company and the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences has passed the clinical research registration review and approved for clinical trials. Ad5-nCoV is constructed by genetic engineering method. It uses replication-defective human type 5 adenovirus as a vector to express the novel coronavirus S antigen and is intended to prevent diseases caused by covi infection.
However, CanSino Biologics Inc. informed the media that it cannot assure that the vaccine can be successfully developed and registered for clinical sale and worldwide vaccination to eliminate covi since clinical trials are underway in Wuhan.
CanSino Biologics Inc. is known for successfully developing and selling the first Ebola vaccine in partnership with the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences.
Since the outbreak, covi has been widely questioned related to the Wuhan Institute of Virology and now the vaccine development has been questioned on the background of the "Novel Coronavirus Emergency Response" exercise in Wuhan.
Although overseas experts have also pointed out the characteristics of the virus's suspected artificial synthesis, there is no direct evidence at present.
Researcher Shi Zhengli of the Wuhan P4 Laboratory of the Wuhan Insititute of Virology is a coronavirus expert. In 2015, she participated in the development of a new coronavirus that can bind to human angiotensin-converting enzyme 2 (ACE2). This coronavirus transmission mode to humans is similar to covid. Last year, the virus research institute also successfully discovered a new type of coronavirus that killed a large number of pigs. After the outbreak in Wuhan in January this year, Chen Wei, a CCP military biochemical weapon expert from the Institute of Biological Engineering of the Military Medical Research Institute of the Chinese Academy of Military Sciences, went south to Wuhan, and it was reported that she secretly took over the P4 laboratory of the Wuhan virus research institute.
Web Refs:
https://www.ntdtv.com/gb/2020/03/23/a102806599.html
http://www.nbd.com.cn/articles/2020-03-18/1417767.html
http://m.xinhuanet.com/hb/2019-09/26/c_1125040756.htm
https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=400167
https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=407064
No comments:
Post a Comment